WAVE Life Sciences Ltd (WVE)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

7 STRAITS VIEW SINGAPORE, SINGAPORE 018936

WaVe Life Sciences Pte. Ltd. operates as a pre-clinical biopharmaceutical company. The Company focuses on utilizing its proprietary synthetic chemistry drug development platform to design, develop, and commercialize stereopure nucleic acid therapeutics. WaVe Life Sciences develops disease-modifying drugs for indications with a high degree of unmet medical need in orphan.

Data based on most recent fiscal year report
Market Cap275.006 Million Shares Outstanding34.29 Million Avg Volume624.19 Thousand
1-Yr BETA vs S&P TR0.921 Current Ratio1.56 Quick Ratio1.56
View SEC Filings from WVE instead.

View recent insider trading info

Funds Holding WVE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding WVE BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

21 Thousand total shares from 5 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HENRY CHRISTIAN O

  • Director
  • CHAIRMAN
0 2020-03-16 1

RA CAPITAL MANAGEMENT, L.P.

RA CAPITAL HEALTHCARE FUND LP

KOLCHINSKY PETER

  • Director
  • 10% Owner
10,874,613 2020-03-13 0

BOLNO PAUL PRESIDENT AND CEO

  • Officer
  • Director
0 2020-03-03 2

VARGEESE CHANDRA SENIOR VP, DRUG DISCOVERY

  • Officer
0 2020-03-03 3

FRANCIS CHRIS SEE REMARKS

  • Officer
0 2020-03-03 2

PANZARA MICHAEL A. CHIEF MEDICAL OFFICER

  • Officer
0 2020-03-03 3

GAIERO DAVID G INTERIM CFO

  • Officer
0 2020-03-03 3

KOLCHINSKY PETER

  • Director
  • 10% Owner
0 2020-01-23 1

RAWCLIFFE ADRIAN CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2020-01-16 1

VERDINE GREGORY L.

  • Director
30,000 2019-11-20 2

TAKANASHI KEN

  • Director
1,561,719 2019-09-17 1

WAGNER HEIDI L

  • Director
0 2019-09-04 2

POTT AMY

  • Director
0 2019-09-04 2

CORRIGAN MARK

  • Director
0 2019-09-04 2

MIURA KOJI

  • Director
0 2019-08-15 1

BALDRY MARK CHIEF COMMERICAL OFFICER

  • Officer
39,000 2019-08-05 2

REGNANTE KEITH CHIEF FINANCIAL OFFICER

  • Officer
29,186 2019-03-07 0

RA CAPITAL MANAGEMENT, LLC

KOLCHINSKY PETER

  • Director
  • 10% Owner
7,775,207 2019-01-24 0

TANAKA MASAHARU

KAGOSHIMA SHINSANGYO SOUSEI INVESTMENT LIMITED PARTNERSHIP

  • Director
  • 10% Owner
No longer subject to file 2017-09-15 0

GUERCIOLINI ROBERTO SEE REMARKS

  • Officer
4,000 2016-12-07 0

WADA TAKESHI

  • Director
0 2016-11-10 0

TANAKA MASAHARU

  • Director
  • 10% Owner
0 2016-11-10 0

MORAN KYLE SEE REMARKS

  • Officer
0 2016-06-16 0

TAKANASHI KEN

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

  • Director
  • 10% Owner
1,697,467 2015-11-10 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

GAIERO DAVID G - Officer INTERIM CFO

2020-03-03 A 18,000 a 18,000 0.00 direct

PANZARA MICHAEL A. - Officer CHIEF MEDICAL OFFICER

2020-03-03 A 36,000 a 36,000 0.00 direct

BOLNO PAUL - Director - Officer PRESIDENT AND CEO

2020-03-03 A 63,000 a 63,000 0.00 direct

VARGEESE CHANDRA - Officer SENIOR VP, DRUG DISCOVERY

2020-03-03 A 36,000 a 36,000 0.00 direct

FRANCIS CHRIS - Officer SEE REMARKS

2020-03-03 A 36,000 a 36,000 0.00 direct

PANZARA MICHAEL A. - Officer CHIEF MEDICAL OFFICER

2020-02-18 S 2,981 $7.85 d 39,349 39,349.00 direct yes

FRANCIS CHRIS - Officer SEE REMARKS

2020-02-18 S 2,708 $7.85 d 31,160 31,160.00 direct yes

VARGEESE CHANDRA - Officer SENIOR VP, DRUG DISCOVERY

2020-02-18 S 3,188 $7.85 d 37,057 37,057.00 direct yes

BOLNO PAUL - Director - Officer PRESIDENT AND CEO

2020-02-18 S 11,451 $7.85 d 319,758 319,758.00 direct yes

GAIERO DAVID G - Officer INTERIM CFO

2020-02-03 S 651 $7.00 d 6,392 6,392.00 direct yes

Elevate your investments